Causal Pathways Between Breast Cancer and Cardiovascular Disease Through Mediator Factors: A Two-Step Mendelian Randomization Analysis
Weilin Lu,Kaiming Li,Haisi Wu,Jinyu Li,Yan Ding,Xiaolin Li,Zhipeng Liu,Huae Xu,Yinxing Zhu
DOI: https://doi.org/10.2147/ijwh.s483139
2024-11-10
International Journal of Women s Health
Abstract:Weilin Lu, 1, &ast Kaiming Li, 2, &ast Haisi Wu, 2, &ast Jinyu Li, 2 Yan Ding, 2 Xiaolin Li, 1 Zhipeng Liu, 3 Huae Xu, 2 Yinxing Zhu 3, 4 1 The First Affiliated Hospital with Nanjing Medical University, Nanjing, People's Republic of China; 2 Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, People's Republic of China; 3 Taizhou Affiliated Hospital of Nanjing University of Chinese Medicine, Taizhou, People's Republic of China; 4 Taizhou People's Hospital affiliated to Nanjing Medical University, Taizhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Huae Xu; Yinxing Zhu, Email ; Background: The causal relationship of breast cancer (BC) with cardiovascular disease (CVD) and the underlying mediating pathways remains elusive. Our study endeavors to investigate the causal association between BC and CVD, with a focus on identifying potential metabolic mediators and elucidating their mediation effects in this causality. Methods: In this study, we conducted two-sample Mendelian randomization (MR) to estimate the causal effect of BC (overall BC, ER+ BC, ER- BC) from the Breast Cancer Association Consortium (BCAC) on CVD including coronary heart disease (CHD), hypertensive heart disease (HHD), ischaemic heart disease (IHD), and heart failure (HF) from the FinnGen consortium. Then, we used two-step MR to evaluate 18 metabolic mediators of the association and calculate the mediated proportions. Results: Genetically predicted ER+ BC was causally associated with an increased risk of CVD including CHD (OR = 1.034, 95% CI: 1.004– 1.065, p = 0.026), HHD (OR = 1.061, 95% CI: 1.002– 1.124, p = 0.041), IHD (OR = 1.034, 95% CI: 1.007– 1.062, p=0.013), and HF (OR = 1.055, 95% CI: 1.013– 1.099, p = 0.010), while no causality was observed for overall BC and ER- BC. Furthermore, high-density lipoprotein cholesterol (HDL-C) was identified as a mediator of the association between ER+BC and CVD, including CHD (with 15.2% proportion)) and IHD (with 15.5% proportion), respectively. Conclusion: This study elucidates the potential causal impact of ER+ BC on subsequent risk of CVD, including CHD, HHD, IHD, and HF. We also outline the metabolic mediator HDL-C as a priority target for preventive measures to reduce excessive risk of CVD among patients diagnosed with ER+BC. Keywords: breast cancer, cardiovascular disease, ER status, Mendelian randomization, metabolic mediators, HDL-C Breast cancer (BC) is the most frequently diagnosed malignant cancer as well as the leading cause of cancer-related mortality in women globally. 1 According to the American Cancer Society, BC stood out as the leading contributor to new cancer cases among females in the United States, comprising a staggering 32% of the total incidences. Besides, it occupied the second-most significant position in terms of mortality rates, accounting for 15% of the female deaths recorded in 2024. 2 BC can be classified into two main subtypes: ER+ and ER-, differentiated by the presence or absence of estrogen receptor (ER) expression on cancer cells. Notably, approximately 70% of BC patients exhibit ER expression, thereby rendering it a pivotal therapeutic target for precision-based treatments. 3 Over the last two decades, with advancements in early detection, precision therapy, and supportive care, there has been a consequent increase in survival following BC diagnosis. However, non-cancer-related mortality, including cardiovascular disease(CVD), cerebrovascular disease, chronic obstructive pulmonary disease (COPD), and Alzheimer's disease, has been increasing in BC survivors. 4 Among them, CVD stands as the primary cause of mortality among women in the United States, posing a significant impediment to achieving optimal outcomes for BC survivors. 5,6 Epidemiological evidence concerning the correlation between BC and CVD remains inconclusive. A population-based cohort of 6641 BC patients who survived at least 10 years demonstrated that an increased risk of newly diagnosed diseases of the circulatory system was observed compared with the general population. 7 Several cohort studies have examined the CVD risks among BC survivors, which showed that women with a history of BC are more predisposed to developing and dying of CVD compared to women without a history of BC. 8–10 However, the latest published meta-analysis indicated that BC is associated with a higher risk of atrial fibrillation, and heart failure when compared to the general population, but not wi -Abstract Truncated-
obstetrics & gynecology